<?xml version="1.0" encoding="UTF-8"?>
<app-group>
 <app id="app1-vaccines-08-00197">
  <title>Supplementary Materials</title>
  <p>The following are available online at 
   <uri xlink:href="https://www.mdpi.com/2076-393X/8/2/197/s1" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.mdpi.com/2076-393X/8/2/197/s1</uri>, Figure S1: Gating strategy for NK-cell degranulation assay (antibody-dependent cellular cytotoxicity, ADCC), Figure S2: Gating strategy for intracellular cytokine staining (ICS) assay, Figure S3: Gating strategy in flow cytometry analysis of target cells for CTL in vivo assay, Figure S4: Immunogenicity of the recombinant vaccine candidates included in the study, Table S1: Amino acid sequences of the M2e fragments comprising the 3M2e protein used in this study, Table S2: Comparison of amino acid sequences of N-terminally extended long alfa-helix fragment of various influenza A HA proteins used in this study, Table S3: Sequence conservation between the vaccination antigens and the corresponding protein fragments of influenza A challenge viruses used in this study.
  </p>
 </app>
</app-group>
